Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

The Agentic Era Redefines Customer Intimacy as AI is Set to Become the Primary Brand Interface

View original at finance.yahoo.com
The Agentic Era Redefines Customer Intimacy as AI is Set to Become the Primary Brand Interface With AI agents leading customer interactions, new Amdocs global research shows CSPs must embed trust, transparency, and distinct personalities into every AI-led experience to drive the next generation of personalization JERSE…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 57% of CSPs today rely on a single AI persona, but only 11% expect that model to continue in the next one to two years

    80% confidence
  • AI agents are no longer just tools; they are becoming the living embodiment of the brand

    80% confidence
  • 56% of CSPs plan to deploy multiple predefined AI personalities in the next one to two years, up from 20% today

    80% confidence
  • Achieving true customer intimacy at scale is no longer just a marketing goal; it is a growth imperative

    80% confidence
  • In the Agentic Era, every AI-led interaction is a brand moment and brands must orchestrate AI personas with rigor and empathy

    80% confidence
  • CSP stakeholders expect most customer interactions to be AI-led within the next two years

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com